UB Paderborn / Katalog / Suche / in CDI

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder

The journal of clinical psychiatry, 2010-08, Vol.71 (8), p.1088

2010

Volltextzugriff (PDF)

Venlafaxine extended release in posttraumatic stress disorder : A sertraline- and placebo-controlled study

Journal of clinical psychopharmacology, 2006-06, Vol.26 (3), p.259-267

2006

Volltextzugriff (PDF)

Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale

International clinical psychopharmacology, 2008-09, Vol.23 (5), p.299

2008

Volltextzugriff (PDF)

Efficacy of venlafaxine XR and placebo in social anxiety disorder: Effects of gender and physical symptoms

European psychiatry, 2007-03, Vol.22, p.S240-S240

2007

Volltextzugriff (PDF)

Predictors of clinical outcome in panic disorder: Analysis of venlafaxine XR short-term treatment studies

European psychiatry, 2007-03, Vol.22, p.S240-S240

2007

Volltextzugriff (PDF)

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder

The journal of clinical psychiatry, 2006-01, Vol.67 (1), p.72

2006

Volltextzugriff (PDF)

Recurrence prevention in patients with recurrent major depression receiving 12 months of treatment with venlafaxine XR

European psychiatry, 2007-03, Vol.22, p.S240-S241

2007

Volltextzugriff (PDF)

Two-year placebo-controlled maintenance study to assess recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression

European psychiatry, 2007-03, Vol.22, p.S241-S241

2007

Volltextzugriff (PDF)

Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression

European psychiatry, 2007-03, Vol.22, p.S239-S240

2007

Volltextzugriff (PDF)

Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study

Primary care companion for CNS disorders, 2011, Vol.13 (1)

2011

Volltextzugriff (PDF)

Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis

The international journal of neuropsychopharmacology, 2009-02, Vol.12 (1), p.23-31

2009

Volltextzugriff (PDF)

A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo

The journal of clinical psychiatry, 2008-10, Vol.69 (10), p.1529

2008

Volltextzugriff (PDF)

P.3.062 Venlafaxine XR and sertraline in PTSD: A placebo-controlled study

European neuropsychopharmacology, 2003-10, Vol.13, p.S380-S380

2003

Volltextzugriff (PDF)

Assessing the Signal Detection Properties of 3 Outcome Scales Used in Clinical Trials of Patients with Generalized Anxiety Disorder

NeuroRx, 2006-07, Vol.3 (3), p.411-411

2006

Volltextzugriff (PDF)

An Analysis of Correlations Among 4 Outcome Scales Employed in Clinical Trials of Patients With Major Depressive Disorder

NeuroRx, 2006-07, Vol.3 (3), p.411-412

2006

Volltextzugriff (PDF)

P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression

European neuropsychopharmacology, 2006, Vol.16, p.S322-S323

2006

Volltextzugriff (PDF)

Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006

NeuroRx, 2006-07, Vol.3 (3), p.407-415

2006

Volltextzugriff (PDF)

Illness severity as a predictor of remission in patients with posttraumatic stress disorder treated with venlafaxine XR or placebo

BIOLOGICAL PSYCHIATRY, 2005, Vol.57 (8), p.113S

2005

Volltextzugriff (PDF)

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial

Archives of general psychiatry, 2006-10, Vol.63 (10), p.1158

2006

Volltextzugriff (PDF)

A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites

Neuropsychopharmacology (New York, N.Y.), 2012-12, Vol.37 (13), p.2830-2836

2012

Volltextzugriff (PDF)

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases

The journal of clinical psychiatry, 2007-08, Vol.68 (8), p.1246

2007

Volltextzugriff (PDF)

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies

International clinical psychopharmacology, 2013-11, Vol.28 (6), p.312

2013

Volltextzugriff (PDF)

Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder

Primary care companion for CNS disorders, 2015, Vol.17 (1)

2015

Volltextzugriff (PDF)

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study

The journal of clinical psychiatry, 2007-07, Vol.68 (7), p.1014

2007

Volltextzugriff (PDF)

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

Current medical research and opinion, 2010-01, Vol.26 (1), p.139-150

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder

Venlafaxine extended release in posttraumatic stress disorder : A sertraline- and placebo-controlled study

Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale

Efficacy of venlafaxine XR and placebo in social anxiety disorder: Effects of gender and physical symptoms

Predictors of clinical outcome in panic disorder: Analysis of venlafaxine XR short-term treatment studies

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder

Recurrence prevention in patients with recurrent major depression receiving 12 months of treatment with venlafaxine XR

Two-year placebo-controlled maintenance study to assess recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression

Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression

Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study

Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis

A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo

P.3.062 Venlafaxine XR and sertraline in PTSD: A placebo-controlled study

Assessing the Signal Detection Properties of 3 Outcome Scales Used in Clinical Trials of Patients with Generalized Anxiety Disorder

An Analysis of Correlations Among 4 Outcome Scales Employed in Clinical Trials of Patients With Major Depressive Disorder

P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression

Abstracts from the ASENT 2006 Annual Meeting March 8–11, 2006

Illness severity as a predictor of remission in patients with posttraumatic stress disorder treated with venlafaxine XR or placebo

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial

A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies

Incidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder

Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

Suchergebnisse filtern